Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Lelli

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Tumori|August 16, 2001
Salvage treatment with epirubicin and/or paclitaxel in metastatic breast cancer patients relapsed after high-dose chemotherapy with peripheral blood progenitor cellsA Tartarone, Z Sirotovà, M Aieta, et al.
Journal of Chemotherapy (Florence, Italy)|January 13, 2000
Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancerG Cilenti, L Tozzi, A Suriano, et al.
Journal of Chemotherapy (Florence, Italy)|December 1, 1990
A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC)G Lelli, M Guaraldi, N Canova, et al.
Journal of Chemotherapy (Florence, Italy)|October 1, 1992
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index)S Tanneberger, G Lelli, A Martoni, et al.
Pathologica|October 30, 1998
[Clear cell sarcoma of soft tissues. Clinico-pathological and ultrastructural analysis of a case in the head-neck region and a literature review]M Bisceglia, I Carosi, G Lelli, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 1989
A phase III study on intermittent versus weekly cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinomaG Lelli, M Casadio, A Farris, et al.
Cancer Treatment Reports|October 1, 1980
High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trialF Pannuti, G Lelli, M Casadio, et al.
Journal of Chemotherapy (Florence, Italy)|December 13, 2007
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancerG Lelli, I Carandina, B Urbini, et al.
Journal of Chemotherapy (Florence, Italy)|July 19, 2003
Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisalG Lelli, M Montanari, G Gilli, et al.
Journal of Chemotherapy (Florence, Italy)|February 1, 1990
Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancerA Martoni, L Ercolino, A Bellucco, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Tumori|August 16, 2001
Salvage treatment with epirubicin and/or paclitaxel in metastatic breast cancer patients relapsed after high-dose chemotherapy with peripheral blood progenitor cellsA Tartarone, Z Sirotovà, M Aieta, et al.
Journal of Chemotherapy (Florence, Italy)|January 13, 2000
Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancerG Cilenti, L Tozzi, A Suriano, et al.
Journal of Chemotherapy (Florence, Italy)|December 1, 1990
A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC)G Lelli, M Guaraldi, N Canova, et al.
Journal of Chemotherapy (Florence, Italy)|October 1, 1992
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index)S Tanneberger, G Lelli, A Martoni, et al.
Pathologica|October 30, 1998
[Clear cell sarcoma of soft tissues. Clinico-pathological and ultrastructural analysis of a case in the head-neck region and a literature review]M Bisceglia, I Carosi, G Lelli, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 1989
A phase III study on intermittent versus weekly cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinomaG Lelli, M Casadio, A Farris, et al.
Cancer Treatment Reports|October 1, 1980
High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trialF Pannuti, G Lelli, M Casadio, et al.
Journal of Chemotherapy (Florence, Italy)|December 13, 2007
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancerG Lelli, I Carandina, B Urbini, et al.
Journal of Chemotherapy (Florence, Italy)|July 19, 2003
Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisalG Lelli, M Montanari, G Gilli, et al.
Journal of Chemotherapy (Florence, Italy)|February 1, 1990
Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancerA Martoni, L Ercolino, A Bellucco, et al.
Pageof 4